Author Correction: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

NPJ Breast Cancer. 2024 Jun 6;10(1):41. doi: 10.1038/s41523-024-00650-6.
No abstract available

Publication types

  • Published Erratum